Based on the team's discovery that an enzyme called CD38, implicated in aging metabolism, is elevated in scleroderma and underlies fibrosis, they created an antibody engineered to selectively ...

An enzyme called CD38 has been discovered by researchers that is responsible for the decrease in nicotinamide adenine dinucleotide (NAD) during aging, a process that is associated with age-related ...

The ecto-enzyme CD38 is gaining momentum as a novel therapeutic target for patients with hematological malignancies, with several anti-CD38 monoclonal antibodies in clinical trials with promising ...

“Targeting the CD38 enzyme is a very innovative concept that could be the next pharmacological approach for fibrosis treatment,” said Varga, also the Frederick Huetwell Professor.

Conversion of mP to ADPR using a standard curve demonstrates that ADPR formation is linear with enzyme. At 12 pM CD38, about 1.5 μM ADPR was produced, which was 10% substrate conversion from 15 ...

Researchers at Mayo Clinic have identified the enzyme, called CD38, that is responsible for the decrease in nicotinamide adenine dinucleotide (NAD) during aging, a process that is associated with ...

CD38 is an enzyme with NAD-depleting and intracellular signaling activity expressed on the cell surface, in intracellular compartments and in mitochondria, and is linked to inflammatory and autoimmune ...

However, immunotherapy targeting CD38/CD3 is proving to be very promising. ... As an extracellular enzyme, CD38 can then catalyze the cleavage of NAD+ into cyclic adenosine diphosphate ribose ...

To uncover the molecular mechanisms regulating ovarian NAD+ loss, first the researchers began by adding another piece of the puzzle: CD38, an enzyme known to be one of the main culprits in ...